YM BioSciences Inc. conference call

    NOTICE OF YM BIOSCIENCES CONFERENCE CALL TO DISCUSS PHASE II DATA FOR
NIMOTUZUMAB IN METASTATIC COLORECTAL CANCER

    MISSISSAUGA, ON, Aug. 5 /CNW/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM,
AIM: YMBA), an oncology company that identifies, develops and commercializes
differentiated products for patients worldwide, will hold a conference call
hosted by Mr. David Allan, Chairman and CEO, at 12:00pm EDT today, August 5,
where members of the professional investment community are invited to discuss
the preliminary results obtained from its open-label, Phase II study
(YMB1000-015) of nimotuzumab in patients with irinotecan-refractory,
metastatic colorectal cancer (mCRC) with management.

   
    CONFERENCE CALL DETAILS

    DATE:                    August 5, 2008

    TIME:                    12:00 PM Eastern Time

    DIAL IN NUMBER:          416 644 3419 and 1 800 731 5774
   

    A live audio webcast of the conference call will be available at
www.ymbiosciences.com.

    About YM BioSciences

    YM BioSciences Inc. is an oncology company that identifies, develops and
commercializes differentiated products for patients worldwide. In addition to
nimotuzumab, the Company is developing AeroLEF(TM), a proprietary,
inhaled-delivery composition of free and liposome-encapsulated fentanyl in
development for the treatment of moderate to severe pain, including cancer
pain.

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that nimotuzumab will continue to demonstrate a competitive
safety profile in ongoing and future clinical trials; that AeroLEF- will
continue to generate positive efficacy and safety data in future clinical
trials; and that YM and its various partners will complete their respective
clinical trials within the timelines communicated in this release. We
undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.


For further information: James Smith, the Equicom Group Inc., Tel. (416)
815-0700 x 229, Email: jsmith(at)equicomgroup.com; Thomas Fechtner, the Trout
Group LLC, Tel. [phone], Email: tfechtner(at)troutgroup.com; Nominated
Adviser, Canaccord Adams Limited, Ryan Gaffney, Tel. [phone]
(YM. YMI YMBA)




END